Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987361 | 0.97 | CNR1 (0.40) | CNR1HTR1ASRCCNR2FFAR1 | |
| SCHEMBL1990962 | 0.93 | CNR1 (0.42) | CNR1HTR1ASRCCNR2ALDH1A1 | |
| SCHEMBL1994923 | 0.93 | CNR1 (0.40) | CNR1CNR2MAOBMAOAALDH1A1 | |
| SCHEMBL1987339 | 0.93 | CNR1 (0.41) | CNR1HTR1ACNR2ADAMTS7ADAMTS5 | |
| SCHEMBL1128273 | 0.93 | CNR1 (0.43) | CNR1HTR1ACNR2 | |
| SCHEMBL1127431 | 0.91 | CNR1 (0.42) | CNR1HTR1ASRCCNR2ALDH1A1 | |
| SCHEMBL1127694 | 0.90 | CNR1 (0.40) | CNR1HTR1ACNR2ADAMTS7ADAMTS5 | |
| SCHEMBL1985069 | 0.90 | CNR1 (0.42) | CNR1CNR2 | |
| SCHEMBL12601847 | 0.86 | CNR1 (0.37) | CNR1SRCFFAR1FFAR4MAOB | |
| SCHEMBL1985030 | 0.86 | CNR1 (0.41) | CNR1HTR1ACNR2ADAMTS7ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383666-B2 | Pyrrole derivatives, preparation of same and therapeutic application thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-8383666-B2 | Pyrrole derivatives, preparation of same and therapeutic application thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| EP-2283008-B1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2011-11-02 | — | — | EP | disclosed |
| US-20110144157-A1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| US-20110144157-A1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2283008-A2 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | Sanofi-aventis (FR) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141533-A2 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141533-A2 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144157-A1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | ARG2, PYCR1, ARG1 | CNR1 548/4885HTR1A 3180/4885SRC 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.